Kyowa Kirin Co Ltd Updates on Recent Developments
Kyowa Kirin Co Ltd has announced that the results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor, will be presented at the American Academy of Dermatology Annual Meeting in March 2025.
Partnership with Kura Oncology
Kyowa Kirin has partnered with Kura Oncology, with Kura Oncology receiving a $330 million upfront payment as part of their collaboration.
Kura Oncology Financial Results
Kura Oncology reported the following financial results for 2024:
- Collaboration revenue
- Net loss
Upcoming Submissions and Investor Conferences
Kura Oncology plans to submit a New Drug Application in Q2 2025. Additionally, the company’s President and CEO will participate in several investor conferences in March 2025, including:
- TD Cowen Health Care Conference
- Barclays Global Healthcare Conference
- Leerink Partners Global Biopharma Conference